Thomas Eldered, who recently left his position as CEO of Recipharm and who is Nanologica’s largest shareholder, is proposed as new member of the Board of Directors to be elected at the Annual General Meeting on May 27.
Thomas Eldered holds a M.Sc. in Industrial and Management Engineering from Linköping Institute of
Technology and is the co-founder of Recipharm AB, where he was also the CEO from 2008–2021.
Before that, Thomas was the Vice President of Recip AB 1995–2007.
The Nomination Committee is in addition proposing re-election of Gisela Sitbon, Mattias Bengtsson,
Eva Byröd, Tomas Kramar, Anders Rabbe and Lena Torlegård. Gisela Sitbon is proposed to continue
as Chairman of the Board.
Nanologica’s Nomination Committee before the Annual General Meeting 2021 consists of
representatives of the Company’s three largest shareholders. The Nomination Committee has the
- Thomas Eldered (Flerie Invest AB) – Chairman of the Nomination Committee
- Mattias Häggblom (Swedbank Robur Medica)
- Nina Rawal (Vega Bianca AB)
Though there are no formal obstacles for a member of the Nomination Committee to take part of a
decision where the member in question is proposed as board member, Thomas Eldered has chosen
to not take part of the Nomination Committee’s work regarding his nomination. He informed the
Nomination Committee of this at the same time as he announced he was available for election as
member of the board.
” We are delighted that Thomas Eldered has been proposed as a new member of the Board of
Nanologica. With his extensive experience from the life science industry, I am convinced that Thomas
will make a strong contribution to Nanologica’s continued development and growth,” says Gisela
Sitbon, Chairman of the Board of Nanologica.
The Nomination Committee’s other resolutions and its statement will be published in conjunction
with the notice to the Annual General Meeting.
Nanologica’s Annual General Meeting 2021 will be held on Thursday May 27, 2021. Notice will be
published on the Company’s website no later than April 29, 2021. Due to the extraordinary situation
as a result of Covid-19, the Annual General Meeting will be carried out through advance voting
(postal voting), in accordance with temporary legislation being in effect in 2021. More information
will be issued in the notice.
For further information, please contact:
Gisela Sitbon, Chairman of the Board of Nanologica
Ph: + 46 70 282 55 58 or e-mail: firstname.lastname@example.org
Nanologica | Forskargatan 20G, SE- 151 36 Södertälje, Sweden | email@example.com
About Nanologica AB (publ)
Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life
science. Nanologica is world-leading in controlling the shape, size, porosity, and surface
characteristics of silica particles. Through the two business areas, Drug Development and
Chromatography, we are serving the industry by providing products for developing better and
cheaper medicine for the benefits of patients. Nanologica operates from the headquarters in
Södertälje, Sweden and Nanologica’s stock (NICA) is listed on Spotlight Stock Market. For further
information, please visit www.nanologica.com.